JP2023011793A5 - - Google Patents

Download PDF

Info

Publication number
JP2023011793A5
JP2023011793A5 JP2022175211A JP2022175211A JP2023011793A5 JP 2023011793 A5 JP2023011793 A5 JP 2023011793A5 JP 2022175211 A JP2022175211 A JP 2022175211A JP 2022175211 A JP2022175211 A JP 2022175211A JP 2023011793 A5 JP2023011793 A5 JP 2023011793A5
Authority
JP
Japan
Prior art keywords
chimeric antisense
antisense oligonucleotide
nucleosides
sequence
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022175211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023011793A (ja
JP7478210B2 (ja
Filing date
Publication date
Priority claimed from JP2019514088A external-priority patent/JP6970187B2/ja
Application filed filed Critical
Publication of JP2023011793A publication Critical patent/JP2023011793A/ja
Publication of JP2023011793A5 publication Critical patent/JP2023011793A5/ja
Application granted granted Critical
Publication of JP7478210B2 publication Critical patent/JP7478210B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022175211A 2016-09-14 2022-11-01 修飾オリゴヌクレオチド及び使用方法 Active JP7478210B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662394738P 2016-09-14 2016-09-14
US201662394739P 2016-09-14 2016-09-14
US62/394,739 2016-09-14
US62/394,738 2016-09-14
JP2019514088A JP6970187B2 (ja) 2016-09-14 2017-09-14 修飾オリゴヌクレオチド及び使用方法
JP2021176346A JP7170820B2 (ja) 2016-09-14 2021-10-28 修飾オリゴヌクレオチド及び使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021176346A Division JP7170820B2 (ja) 2016-09-14 2021-10-28 修飾オリゴヌクレオチド及び使用方法

Publications (3)

Publication Number Publication Date
JP2023011793A JP2023011793A (ja) 2023-01-24
JP2023011793A5 true JP2023011793A5 (cg-RX-API-DMAC7.html) 2023-04-17
JP7478210B2 JP7478210B2 (ja) 2024-05-02

Family

ID=59955744

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019514088A Expired - Fee Related JP6970187B2 (ja) 2016-09-14 2017-09-14 修飾オリゴヌクレオチド及び使用方法
JP2021176346A Expired - Fee Related JP7170820B2 (ja) 2016-09-14 2021-10-28 修飾オリゴヌクレオチド及び使用方法
JP2022175211A Active JP7478210B2 (ja) 2016-09-14 2022-11-01 修飾オリゴヌクレオチド及び使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2019514088A Expired - Fee Related JP6970187B2 (ja) 2016-09-14 2017-09-14 修飾オリゴヌクレオチド及び使用方法
JP2021176346A Expired - Fee Related JP7170820B2 (ja) 2016-09-14 2021-10-28 修飾オリゴヌクレオチド及び使用方法

Country Status (13)

Country Link
US (3) US10793859B2 (cg-RX-API-DMAC7.html)
EP (1) EP3512949A1 (cg-RX-API-DMAC7.html)
JP (3) JP6970187B2 (cg-RX-API-DMAC7.html)
KR (3) KR20240010761A (cg-RX-API-DMAC7.html)
CN (1) CN109952378B (cg-RX-API-DMAC7.html)
AU (2) AU2017326372B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019004911A2 (cg-RX-API-DMAC7.html)
CA (1) CA3037042A1 (cg-RX-API-DMAC7.html)
IL (2) IL315071A (cg-RX-API-DMAC7.html)
MA (1) MA46422A (cg-RX-API-DMAC7.html)
MX (2) MX2019002960A (cg-RX-API-DMAC7.html)
TW (1) TWI769177B (cg-RX-API-DMAC7.html)
WO (1) WO2018053185A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017326372B2 (en) 2016-09-14 2023-12-07 Janssen Biopharma, Inc. Modified oligonucleotides and methods of use
IL273274B2 (en) * 2017-09-14 2023-12-01 Janssen Biopharma Llc Modified nucleoside phosphoramidites
SG11202002149XA (en) 2017-09-14 2020-04-29 Janssen Biopharma Inc Galnac derivatives
US20200147124A1 (en) * 2018-11-08 2020-05-14 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20230250125A1 (en) * 2020-04-01 2023-08-10 Janssen Biopharma, Inc. Nucleic acid polymers
CA3187388A1 (en) * 2020-07-27 2022-02-03 Jin Hong Hbv binding oligonucleotides and methods of use
CN114057816B (zh) * 2020-07-30 2025-02-11 浙江柏拉阿图医药科技有限公司 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
US20240073008A1 (en) 2021-01-12 2024-02-29 Nec Corporation Secure computation system, secure computation server apparatus, secure computation method, and secure computation program
KR20240131441A (ko) 2022-01-10 2024-08-30 오스퍼바이오 테라퓨틱스 인크. B형 간염 바이러스(hbv) 발현의 조절
TW202508607A (zh) * 2023-05-19 2025-03-01 大陸商北京炫景瑞醫藥科技有限公司 雙股寡核苷酸及其共軛物和用途
TW202608468A (zh) * 2024-05-13 2026-03-01 美商基利科學股份有限公司 組合療法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT76094A (en) 1994-03-18 1997-06-30 Lynx Therapeutics Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
BRPI0008131B8 (pt) 1999-02-12 2021-05-25 Daiichi Sankyo Co Ltd composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
ATE356824T1 (de) 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
JP4151751B2 (ja) 1999-07-22 2008-09-17 第一三共株式会社 新規ビシクロヌクレオシド類縁体
HK1049339B (en) * 1999-09-10 2008-06-27 Geron Corporation Oligonucleotide n3'-p5' thiophosphoramidates: their synthesis and use
AU2001227965A1 (en) 2000-01-21 2001-07-31 Geron Corporation 2'-arabino-fluorooligonucleotide n3'-p5'phosphoramidates: their synthesis and use
US7563618B2 (en) * 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
CA2442092A1 (en) 2001-03-26 2002-10-17 Ribozyme Pharmaceuticals, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
US7923547B2 (en) * 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2005003314A2 (en) * 2003-06-27 2005-01-13 Isis Pharmaceuticals, Inc. A method of selecting an active oligonucleotide predictive model
DE602004031975D1 (de) 2003-11-04 2011-05-05 Geron Corp Rna-amidate und thioamidateur rnai
KR20080036650A (ko) * 2005-08-17 2008-04-28 시르나 쎄러퓨틱스 인코퍼레이티드 Rna 간섭을 매개하는 화학적으로 변형된 짧은 간섭 핵산분자
WO2008011473A2 (en) * 2006-07-19 2008-01-24 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hbxip
ES2651308T3 (es) * 2009-10-16 2018-01-25 Glaxo Group Limited Inhibidores antisentido de HBV
WO2011060557A1 (en) 2009-11-20 2011-05-26 Governors Of The University Of Alberta Method for selection of aptamers
WO2011139911A2 (en) * 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
SI3505528T1 (sl) * 2011-04-21 2021-04-30 Glaxo Group Limited Modulacija izražanja virusa hepatitisa B (HBV)
PT2726613T (pt) 2011-06-30 2018-10-26 Arrowhead Pharmaceuticals Inc Composições e métodos para inibição da expressão de genes do vírus da hepatite b
WO2013159109A1 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
WO2014028739A1 (en) * 2012-08-15 2014-02-20 Isis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified capping protocols
US9228189B2 (en) 2012-10-26 2016-01-05 Geron Corporation C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
TWI769565B (zh) * 2014-11-10 2022-07-01 美商阿尼拉製藥公司 B型肝炎病毒(HBV)iRNA組成物及其用途方法
US10059940B2 (en) * 2015-01-27 2018-08-28 Minghong Zhong Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents
AU2017326372B2 (en) 2016-09-14 2023-12-07 Janssen Biopharma, Inc. Modified oligonucleotides and methods of use

Similar Documents

Publication Publication Date Title
IL315071A (en) Modified oligonucleotides and pharmaceutical compositions
US12503698B2 (en) GalNAc derivatives
JP4236812B2 (ja) オリゴヌクレオチド類似体
US5596091A (en) Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US6670461B1 (en) Oligonucleotide analogues
US8080644B2 (en) Oligonucleotide analogues
JP2021072862A5 (cg-RX-API-DMAC7.html)
WO1998000564A1 (en) Methods and compositions for sequence-specific hybridization of rna by 2'-5' oligonucleotides
JPH08508491A (ja) ホスホジエステル結合をアミド結合に置き換えたオリゴヌクレオチド
JP2625257B2 (ja) 主鎖修飾されたオリゴヌクレオチド類似体
ES2244957T3 (es) Oligonucleotidos modificados, su preparacion, asi como su empleo.
JPH05505101A (ja) オリゴヌクレオチド療法における三重らせん形成
JP6542662B2 (ja) オリゴヌクレオチドアナログのボロン酸結合体
JP2019534862A (ja) ホスホルアミダイト化学を使用する骨格修飾モルホリノオリゴヌクレオチド及びキメラの合成
JP2019529406A5 (cg-RX-API-DMAC7.html)
JPH10504719A (ja) 非ヌクレオチド部分を有するポリヌクレオチド試薬、ならびに合成および使用に関連する方法
JPS62502338A (ja) 立体規則性ポリヌクレオチド結合ポリマ−
EP0531436A4 (en) Sequence-specific nonphotoactivated crosslinking agents which bind to the major groove of duplex dna
JP2021515784A5 (cg-RX-API-DMAC7.html)
CN119528986B (zh) 一种核苷类似物及其在降低寡核苷酸药物脱靶活性中的应用
JP2020525502A (ja) 分子を経膜送達するための化合物及び方法
CN104321334A (zh) 三环核苷及由其制备的低聚化合物
CN121194983A (zh) 5'-膦酸酯修饰的核苷类似物及其制备的寡核苷酸
WO2021000380A1 (zh) 修饰核苷、核苷酸和修饰核酸聚合物及其制备方法和应用
JP2020521491A5 (cg-RX-API-DMAC7.html)